CompletedNot Applicable

A Study of SPG Block for Opioid Withdrawal

United States3 participantsStarted 2023-02-03

Plain-language summary

Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study investigating whether blocking the SPG helps reduce withdrawal symptoms in OUD. This study does not involve treatment or induction onto medications. It is a proof of principal study only. We will recruit non-treatment seeking subjects with OUD who are admitted to the research unit for all procedures.

Who can participate

Age range22 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Opioid Use Disorder, moderate to severe * Ages 22 to 50 * Lives in New York City, able to travel for visits * Willing to be admitted to an inpatient unit Exclusion Criteria: * Medical disorder, for who study participation could be deleterious (neurologic, cardiac, renal or infectious disease * Hypertension: BP \> 150/100 * Elevated liver function tests (AST, ALT) \> 3x normal * Having a painful medical illness for which opioids are needed (including upcoming surgery).

What they're measuring

enrollment: percent screened subjects who enroll

Timeframe: 4 weeks

retention: percent enrolled subjects who complete

Timeframe: 4 weeks

tolerability: percent adverse events, if any

Timeframe: 4 weeks

Trial details

NCT IDNCT04946656

SponsorNew York State Psychiatric Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-03

View on ClinicalTrials.gov More Opioid Use Disorder trials